KRAS gene mutations are one of the main causes of lung adenocarcinoma, and the activation of KRAS in lung cancer can enhance the activity of SREBP through the ERK-mTORC1 pathway, thereby stimulating the synthesis of fatty acids (Gouw et al., 2017). Here, KRAS is linked to lung cancer.